skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development

Abstract

A number of drivers and developments suggest that microdosing and other phase 0 applications will experience increased utilization in the near-to-medium future. Increasing costs of drug development and ethical concerns about the risks of exposing humans and animals to novel chemical entities are important drivers in favor of these approaches, and can be expected only to increase in their relevance. An increasing body of research supports the validity of extrapolation from the limited drug exposure of phase 0 approaches to the full, therapeutic exposure, with modeling and simulations capable of extrapolating even non-linear scenarios. An increasing number of applications and design options demonstrate the versatility and flexibility these approaches offer to drug developers including the study of PK, bioavailability, DDI, and mechanistic PD effects. PET microdosing allows study of target localization, PK and receptor binding and occupancy, while Intra-Target Microdosing (ITM) allows study of local therapeutic-level acute PD coupled with systemic microdose-level exposure. Applications in vulnerable populations and extreme environments are attractive due to the unique risks of pharmacotherapy and increasing unmet healthcare needs. Lastly, all phase 0 approaches depend on the validity of extrapolation from the limited-exposure scenario to the full exposure of therapeutic intent, but in the finalmore » analysis the potential for controlled human data to reduce uncertainty about drug properties is bound to be a valuable addition to the drug development process.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8]
  1. Burt Consultancy, Durham, NC (United States)
  2. US Food and Drug Administration, Silver Spring MD (United States). Center for Drug Evaluation and Research, Office of Clinical Pharmacology (OCP), Office of Translational Sciences; Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
  3. Univ. of Lincoln (United Kingdom). School of Pharmacy, Joseph Banks Lab.
  4. LTV Consulting, Davis CA (United States); BioCore, Seoul (South Korea)
  5. US Food and Drug Administration, Silver Spring MD (United States). Center for Drug Evaluation and Research, Office of Clinical Pharmacology (OCP), Office of Translational Sciences
  6. Erasmus MC Sophia Children's Hospital, Rotterdam (The Netherlands)
  7. RIKEN Innovation Center, Yokohama, Kanagawa (Japan). Sugiyama Lab.
  8. Univ. of Manchester (United Kingdom). Centre for Applied Pharmacokinetic Research; Univ. of California, San Francisco, CA (United States). Dept. of Bioengineering and Therapeutic Sciences
Publication Date:
Research Org.:
Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Org.:
USDOE Office of Science (SC); Netherlands Organisation for Health Research (ZonMw)
OSTI Identifier:
1376052
Resource Type:
Accepted Manuscript
Journal Name:
Clinical and Translational Science
Additional Journal Information:
Journal Volume: 9; Journal Issue: 2; Journal ID: ISSN 1752-8054
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Burt, T., Yoshida, K., Lappin, G., Vuong, L., John, C., de Wildt, SN, Sugiyama, Y., and Rowland, M. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. United States: N. p., 2016. Web. doi:10.1111/cts.12390.
Burt, T., Yoshida, K., Lappin, G., Vuong, L., John, C., de Wildt, SN, Sugiyama, Y., & Rowland, M. Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. United States. doi:10.1111/cts.12390.
Burt, T., Yoshida, K., Lappin, G., Vuong, L., John, C., de Wildt, SN, Sugiyama, Y., and Rowland, M. Fri . "Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development". United States. doi:10.1111/cts.12390. https://www.osti.gov/servlets/purl/1376052.
@article{osti_1376052,
title = {Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development},
author = {Burt, T. and Yoshida, K. and Lappin, G. and Vuong, L. and John, C. and de Wildt, SN and Sugiyama, Y. and Rowland, M.},
abstractNote = {A number of drivers and developments suggest that microdosing and other phase 0 applications will experience increased utilization in the near-to-medium future. Increasing costs of drug development and ethical concerns about the risks of exposing humans and animals to novel chemical entities are important drivers in favor of these approaches, and can be expected only to increase in their relevance. An increasing body of research supports the validity of extrapolation from the limited drug exposure of phase 0 approaches to the full, therapeutic exposure, with modeling and simulations capable of extrapolating even non-linear scenarios. An increasing number of applications and design options demonstrate the versatility and flexibility these approaches offer to drug developers including the study of PK, bioavailability, DDI, and mechanistic PD effects. PET microdosing allows study of target localization, PK and receptor binding and occupancy, while Intra-Target Microdosing (ITM) allows study of local therapeutic-level acute PD coupled with systemic microdose-level exposure. Applications in vulnerable populations and extreme environments are attractive due to the unique risks of pharmacotherapy and increasing unmet healthcare needs. Lastly, all phase 0 approaches depend on the validity of extrapolation from the limited-exposure scenario to the full exposure of therapeutic intent, but in the final analysis the potential for controlled human data to reduce uncertainty about drug properties is bound to be a valuable addition to the drug development process.},
doi = {10.1111/cts.12390},
journal = {Clinical and Translational Science},
number = 2,
volume = 9,
place = {United States},
year = {2016},
month = {2}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 22 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Pediatric microdose and microtracer studies using 14 C in Europe
journal, July 2015

  • Turner, Ma; Mooij, Mg; Vaes, Whj
  • Clinical Pharmacology & Therapeutics, Vol. 98, Issue 3
  • DOI: 10.1002/cpt.163

A pharmacokinetic evaluation of five H 1 antagonists after an oral and intravenous microdose to human subjects
journal, March 2009


A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer
journal, August 2015

  • Fujita, Ken-ichi; Yoshino, Etsuko; Kawara, Kaori
  • Cancer Chemotherapy and Pharmacology, Vol. 76, Issue 4
  • DOI: 10.1007/s00280-015-2844-2

Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position
journal, February 2013

  • Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.
  • Clinical Pharmacology & Therapeutics, Vol. 94, Issue 1
  • DOI: 10.1038/clpt.2013.34

Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
journal, November 2013


Big physics, small doses: the use of AMS and PET in human microdosing of development drugs
journal, March 2003

  • Lappin, Graham; Garner, R. Colin
  • Nature Reviews Drug Discovery, Vol. 2, Issue 3
  • DOI: 10.1038/nrd1037

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study
journal, August 2011

  • Maeda, K.; Ikeda, Y.; Fujita, T.
  • Clinical Pharmacology & Therapeutics, Vol. 90, Issue 4
  • DOI: 10.1038/clpt.2011.142

Microdosing Studies in Children: A US Regulatory Perspective
journal, July 2015

  • Roth-Cline, M.; Nelson, Rm
  • Clinical Pharmacology & Therapeutics, Vol. 98, Issue 3
  • DOI: 10.1002/cpt.165

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions
journal, July 2012

  • Zhao, P.; Rowland, M.; Huang, S-M
  • Clinical Pharmacology & Therapeutics, Vol. 92, Issue 1
  • DOI: 10.1038/clpt.2012.68

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA.
journal, July 1990

  • Turteltaub, K. W.; Felton, J. S.; Gledhill, B. L.
  • Proceedings of the National Academy of Sciences, Vol. 87, Issue 14
  • DOI: 10.1073/pnas.87.14.5288

Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
journal, October 2011


Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development
journal, September 2003

  • Bergstr�m, Mats; Grahn�n, Anders; L�ngstr�m, Bengt
  • European Journal of Clinical Pharmacology, Vol. 59, Issue 5-6
  • DOI: 10.1007/s00228-003-0643-x

Effective Use of Microdosing and Positron Emission Tomography (PET) Studies on New Drug Discovery and Development
journal, January 2009

  • Sugiyama, Yuichi
  • Drug Metabolism and Pharmacokinetics, Vol. 24, Issue 2
  • DOI: 10.2133/dmpk.24.127

Hepatic and Intestinal Drug Transporters: Prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms
journal, January 2013


Clinical Relevance of Liquid Chromatography Tandem Mass Spectrometry as an Analytical Method in Microdose Clinical Studies
journal, April 2011


Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats
journal, August 2015


Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
journal, April 2013


Use of Microdose Phenotyping to Individualise Dosing of Patients
journal, April 2015

  • Hohmann, Nicolas; Haefeli, Walter E.; Mikus, Gerd
  • Clinical Pharmacokinetics, Vol. 54, Issue 9
  • DOI: 10.1007/s40262-015-0278-y

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions
journal, February 2013

  • Halama, B.; Hohmann, N.; Burhenne, J.
  • Clinical Pharmacology & Therapeutics, Vol. 93, Issue 6
  • DOI: 10.1038/clpt.2013.27

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography
journal, March 1996

  • Bench, C. J.; Lammerstma, A. A.; Grasby, P. M.
  • Psychopharmacology, Vol. 124, Issue 1-2
  • DOI: 10.1007/BF02245614

Use of Accelerator Mass Spectrometry to Measure the Pharmacokinetics and Peripheral Blood Mononuclear Cell Concentrations of Zidovudine
journal, July 2008

  • Vuong, Le T.; Ruckle, Jon L.; Blood, Arlin B.
  • Journal of Pharmaceutical Sciences, Vol. 97, Issue 7
  • DOI: 10.1002/jps.21160

Imaging in the Study of Membrane Transporters
journal, April 2013


Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
journal, February 2011


Ethics at Phase 0: Clarifying the Issues
journal, December 2007


An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development
journal, September 2015

  • Yamashita, Shinji; Kataoka, Makoto; Suzaki, Yuki
  • Journal of Pharmaceutical Sciences, Vol. 104, Issue 9
  • DOI: 10.1002/jps.24499

Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice
journal, December 2007

  • Kinders, R.; Parchment, R. E.; Ji, J.
  • Molecular Interventions, Vol. 7, Issue 6
  • DOI: 10.1124/mi.7.6.9

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
journal, September 2006

  • Suntharalingam, Ganesh; Perry, Meghan R.; Ward, Stephen
  • New England Journal of Medicine, Vol. 355, Issue 10
  • DOI: 10.1056/NEJMoa063842

Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials?
journal, December 2009


Microdosing of protein drugs
journal, November 2015

  • Rowland, M.
  • Clinical Pharmacology & Therapeutics, Vol. 99, Issue 2
  • DOI: 10.1002/cpt.275

Can Animal Models of Disease Reliably Inform Human Studies?
journal, March 2010


Blood sample volumes in child health research: review of safe limits
journal, September 2010

  • Howie, Stephen RC
  • Bulletin of the World Health Organization, Vol. 89, Issue 1
  • DOI: 10.2471/BLT.10.080010

Molecular imaging in drug development
journal, July 2008

  • Willmann, Jürgen K.; van Bruggen, Nicholas; Dinkelborg, Ludger M.
  • Nature Reviews Drug Discovery, Vol. 7, Issue 7
  • DOI: 10.1038/nrd2290

Approaches using molecular imaging technology — use of PET in clinical microdose studies
journal, June 2011


Microdosing and drug development: past, present and future
journal, March 2013

  • Lappin, Graham; Noveck, Robert; Burt, Tal
  • Expert Opinion on Drug Metabolism & Toxicology, Vol. 9, Issue 7
  • DOI: 10.1517/17425255.2013.786042

Transporters as a determinant of drug clearance and tissue distribution
journal, April 2006

  • Shitara, Yoshihisa; Horie, Toshiharu; Sugiyama, Yuichi
  • European Journal of Pharmaceutical Sciences, Vol. 27, Issue 5
  • DOI: 10.1016/j.ejps.2005.12.003

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
journal, July 2014

  • Rose, R. H.; Neuhoff, S.; Abduljalil, K.
  • CPT Pharmacometrics Syst. Pharmacol., Vol. 3, Issue 7
  • DOI: 10.1038/psp.2014.24

Off-Label Drug Use in Pediatric Patients
journal, April 2012

  • Kimland, E.; Odlind, V.
  • Clinical Pharmacology & Therapeutics, Vol. 91, Issue 5
  • DOI: 10.1038/clpt.2012.26

Challenges for drug studies in children: CYP3A phenotyping as example
journal, January 2009



journal, November 2015


A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease
journal, September 2006


Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs
journal, September 2006


Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
journal, May 2014

  • Cook, David; Brown, Dearg; Alexander, Robert
  • Nature Reviews Drug Discovery, Vol. 13, Issue 6
  • DOI: 10.1038/nrd4309

A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing study
journal, May 2011

  • Minamide, Yoshiyuki; Osawa, Yukio; Nishida, Hiroshi
  • Journal of Separation Science, Vol. 34, Issue 13
  • DOI: 10.1002/jssc.201100089

Application of pharmacokinetics–pharmacodynamics/clinical response modeling and simulation for biologics drug development
journal, December 2012

  • Zhao, Liang; Shang, Elizabeth Y.; Sahajwalla, Chandrahas G.
  • Journal of Pharmaceutical Sciences, Vol. 101, Issue 12
  • DOI: 10.1002/jps.23330

Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans
journal, November 2010

  • Watanabe, Takao; Kusuhara, Hiroyuki; Sugiyama, Yuichi
  • Journal of Pharmacokinetics and Pharmacodynamics, Vol. 37, Issue 6
  • DOI: 10.1007/s10928-010-9176-y

The role of DNA adducts in chemical carcinogenesis
journal, June 1998


Adverse drug reactions associated with antiretroviral therapy during pregnancy
journal, November 2014


Improved early clinical development through human microdosing studies
journal, July 2005


Pediatric Microdose Study of [14C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept
journal, September 2014

  • Mooij, Miriam G.; van Duijn, Esther; Knibbe, Catherijne A. J.
  • Clinical Pharmacokinetics, Vol. 53, Issue 11
  • DOI: 10.1007/s40262-014-0176-8

Early human studies of investigational agents: dose or microdose?
journal, March 2009


Drug-induced mitochondrial dysfunction and cardiotoxicity
journal, November 2015

  • Varga, Zoltán V.; Ferdinandy, Peter; Liaudet, Lucas
  • American Journal of Physiology-Heart and Circulatory Physiology, Vol. 309, Issue 9
  • DOI: 10.1152/ajpheart.00554.2015

Commentary: The phase 0 microdosing concept
journal, January 2006


American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process
journal, April 2007

  • Bertino, Joseph S.; Greenberg, Howard E.; Reed, Michael D.
  • The Journal of Clinical Pharmacology, Vol. 47, Issue 4
  • DOI: 10.1177/0091270006299092

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance
journal, March 2011

  • Henderson, Paul T.; Li, Tao; He, Miaoling
  • International Journal of Cancer, Vol. 129, Issue 6
  • DOI: 10.1002/ijc.25814

Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing
journal, January 2012

  • Ieiri, Ichiro; Fukae, Masato; Maeda, Kazuya
  • Int. Journal of Clinical Pharmacology and Therapeutics, Vol. 50, Issue 10
  • DOI: 10.5414/CP201763

Lead PK Commentary: Predicting Human Pharmacokinetics
journal, October 2011

  • Rowland, Malcolm; Benet, Leslie Z.
  • Journal of Pharmaceutical Sciences, Vol. 100, Issue 10
  • DOI: 10.1002/jps.22637

Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene
journal, December 2000

  • Lightfoot, T. J.; Coxhead, J. M.; Cupid, B. C.
  • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, Vol. 472, Issue 1-2
  • DOI: 10.1016/S1383-5718(00)00134-0

The role of molecular imaging in modern drug development
journal, July 2014


Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
journal, March 2010

  • Dijkers, E. C.; Oude Munnink, T. H.; Kosterink, J. G.
  • Clinical Pharmacology & Therapeutics, Vol. 87, Issue 5
  • DOI: 10.1038/clpt.2010.12

Ethical, legal, and social implications (ELSI) of microdose clinical trials
journal, June 2011


Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers
journal, June 2011

  • Lappin, Graham; Shishikura, Yoko; Jochemsen, Roeline
  • European Journal of Pharmaceutical Sciences, Vol. 43, Issue 3
  • DOI: 10.1016/j.ejps.2011.04.009

Microdose Study of 14C-Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects
journal, November 2010

  • Tozuka, Z.; Kusuhara, H.; Nozawa, K.
  • Clinical Pharmacology & Therapeutics, Vol. 88, Issue 6
  • DOI: 10.1038/clpt.2010.206

Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing
journal, January 2012


Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
journal, January 2013


Characterization of Oxaliplatin−DNA Adduct Formation in DNA and Differentiation of Cancer Cell Drug Sensitivity at Microdose Concentrations
journal, December 2007

  • Hah, Sang Soo; Sumbad, Rhoda A.; de Vere White, Ralph W.
  • Chemical Research in Toxicology, Vol. 20, Issue 12
  • DOI: 10.1021/tx700376a

Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans
journal, July 2009


Microdosing Studies in Humans: The Role of Positron Emission Tomography
journal, January 2008


Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
journal, August 2014


Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages
journal, May 2015

  • Vlaming, Mlh; van Duijn, E.; Dillingh, Mr
  • Clinical Pharmacology & Therapeutics, Vol. 98, Issue 2
  • DOI: 10.1002/cpt.131

Novel strategies for microdose studies using non-radiolabeled compounds
journal, June 2011


Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study
journal, June 2011

  • Maeda, K.; Takano, J.; Ikeda, Y.
  • Clinical Pharmacology & Therapeutics, Vol. 90, Issue 2
  • DOI: 10.1038/clpt.2011.108

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
journal, May 2012


Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans: Midazolam microdosing
journal, January 2015

  • Hohmann, Nicolas; Kocheise, Franziska; Carls, Alexandra
  • British Journal of Clinical Pharmacology, Vol. 79, Issue 2
  • DOI: 10.1111/bcp.12502

Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects
journal, May 2011

  • Kusuhara, H.; Ito, S.; Kumagai, Y.
  • Clinical Pharmacology & Therapeutics, Vol. 89, Issue 6
  • DOI: 10.1038/clpt.2011.36

Applications of accelerator MS in pediatric drug evaluation
journal, August 2012


Drug absorption, distribution, metabolism and excretion considerations in critically ill adults
journal, May 2013


    Works referencing / citing this record: